LSL Pharma Group Inc.
LSL.V
TSX
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -281.20K | -189.50K | 3.21M | -283.00K | -377.10K |
Total Depreciation and Amortization | 511.00K | 410.40K | 339.30K | 259.50K | 252.90K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 526.90K | 463.70K | -3.00M | 345.30K | 567.10K |
Change in Net Operating Assets | 318.00K | -334.80K | -230.70K | -385.70K | -521.10K |
Cash from Operations | 1.07M | 349.80K | 322.90K | -63.80K | -78.20K |
Capital Expenditure | -318.00K | -283.60K | 764.40K | -876.90K | -678.90K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -800.10K | -22.00K | -1.54M |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -393.90K | -281.20K | -1.49M | -122.40K | -148.40K |
Cash from Investing | -711.90K | -564.70K | -1.53M | -1.02M | -2.37M |
Total Debt Issued | 5.63M | 3.76M | 6.24M | 1.76M | 438.00K |
Total Debt Repaid | -745.00K | -641.50K | -3.89M | -957.00K | -1.17M |
Issuance of Common Stock | -- | -- | 0.00 | 960.00K | 5.29M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -593.00K | -478.00K | -530.00K | -403.00K | -889.00K |
Cash from Financing | 3.10M | 1.84M | 1.30M | 993.50K | 2.68M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 3.46M | 1.63M | 94.30K | -91.60K | 235.30K |